Maintenance infliximab delayed loss of response in active Crohn disease
- Budesonide and mesalazine in active Crohn’s disease: a comparison of the effects on quality of life. // American Journal of Gastroenterology;Mar2002, Vol. 97 Issue 3, p649
OBJECTIVES:Controlled ileal release budesonide and slow release mesalazine are both used to treat mild to moderate active Crohnâ€™s disease, although data show that budesonide is more effective in inducing remission. When comparing different treatment options, the effects of agents on...
- Review: Infliximab increases response and remission rates in fistulizing or treatment-resistant Crohn disease. Belluzzi, Andrea // ACP Journal Club;Nov/Dec2002, Vol. 137 Issue 3, p91
Discusses research being done on the safety and efficacy of infliximab in patients with Crohn's disease. Reference to study by J.K. Marshall and colleagues; Sources of data; Results and conclusion.
- Infliximab, azathioprine, or combination therapy for Crohn's disease. // Inflammatory Bowel Disease Monitor;2010, Vol. 11 Issue 1, p22
No abstract available.
- A patient with Crohn's disease and new symptoms. Singer, Karl // Patient Care;8/15/2000, Vol. 34 Issue 15, p115
Presents a case of a patient with Crohn's disease. Use of prednisone for the initial treatment of the patient; Effect of using azathioprine; Hypersensitivity reaction to azathioprine; Occurrence of defervescence; Discontinued use of antibiotics and corticosteroids.
- Inflammatory Bowel Diseases: Early introduction of biologic therapy improves Crohn's disease outcomes. // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1
The article focuses on a study, according to which introducing sophisticated biologic therapies early in the course of treatment for Crohn's disease improves response to medication and reduces the need for surgery.
- Many biologics in clinical trials for Crohn's disease. Pfeiffer, Naomi // Drug Topics;6/21/2004, Vol. 148 Issue 12, pHSE8
This article examines the efficacy of infliximab and other biologics used in the management of Crohn's disease. Data from the first major national registry of Crohn's disease patients compared the long-term safety profile of infliximab with standard treatments and found all other drugs similarly...
- Balancing the risks and benefits of prolonged use of infliximab. Schölmerich, Jürgen // Gut;Apr2009, Vol. 58 Issue 4, p477
In this article, the author discusses the result of a study conducted in Leuven, Belgium to determine the efficacy on the use of infliximab in Crohn's disease. The result of the study shows that 614 patients, comprising of individual having luminal disease while 25 percent having fistulising...
- Clinical Nutrition. // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1
The article focuses on a research in which researchers from the Virginia Polytechnic Institute & State University, Blacksburg, Virginia, have discovered important information on the efficacy of conjugated linoleic acid in treating Crohn's disease.
- New indication. // Formulary;Feb2008, Vol. 43 Issue 2, p40
The article discusses the approval of natalizumab, a drug marketed as Tysabri, for the treatment of moderate-to-severe Crohn's disease (CD). The drug was approved on January 14, 2008, after positive results were indicated in the three randomized, double-blind controlled trials that were...